Indian company just did it ! - Zydus pioneers a breakthrough with LIPAGLYN - first molecule from the Indian company
The Zydus Group announced a breakthrough in its research efforts with Lipaglyn TM (Saroglitazar), a novel drug targeted at bridging an unmet healthcare need for treating Diabetic Dyslipidemia or Hypertriglyceridemia in Type II diabetes, not controlled by statins alone. The drug has been approved for launch in India by the Drug Controller General of India (DCGI). With a novel action that offers lipid and glucose lowering effects in one molecule, Lipaglyn TM is the first Glitazar to be approved anywhere in the world.



